ÂÜÀòÂÒÂ×

Bjorn Bolinder is an accomplished executive with extensive experience in health economics, outcomes research, and market access strategy within the pharmaceutical industry. Currently, Bjorn serves as the Head of Real World Evidence Generation and Digital Data Innovation at AstraZeneca, along with the role of Executive Director of US HEOR Oncology. Prior to this, Bjorn held strategic leadership positions at Bristol-Myers Squibb and Axecon LLC, where significant contributions included overseeing HEOR development across oncology portfolios and providing consulting services to life sciences firms. Bjorn's career at Merck involved leadership in market access and health outcomes, while earlier roles at Johnson & Johnson and sanofi-aventis focused on early value assessment and strategic planning for health outcomes research. Bjorn holds an MBA in Finance from Rutgers University and a BSc in Cost Revenue Analysis and Health Economics from the Stockholm School of Economics.